Local researchers need your help to test whether an anti-viral drug can prevent COVID.
The drug Molnupiravir from Merck already has an emergency use authorization for treating COVID after a positive test or onset of symptoms, but the team at Seattle’s Fred Hutchinson Cancer Research Center is now testing Molnupiravir to see if it’s effective at preventing COVID from taking hold if you’re exposed.
The public health experts at UW’s Institute for Health Metrics and Evaluation have stressed and continue to stress the importance of these anti-viral drugs in our COVID strategy because they can be as much as 90% effective at preventing death from the illness caused by the SARS-CoV-2 virus.
To join the trial you have to be at least 18 years old, and you have to live with someone who has had a positive COVID test within three days AND at least one symptom within three days.
Click here to learn more about the trial and to see if you qualify.
